CervoMed Phase 2b DLB data show greater benefit in patients without AD co-pathology

CervoMed Inc.

At pTau181 <21 pg/mL, neflamapimod showed CDR-SB improvement of -1.11 vs placebo (p=0.005) in within-participant analysis.
PK/PD analyses identified therapeutic trough concentration threshold of 4 ng/mL; DP Batch B achieved this in 75% of patients vs 50% for Batch A.
Planned Phase 3 trial will use pTau181 <21 pg/mL enrichment, expecting 80-90% of patients without AD co-pathology.
Data presented March 21, 2026 at AD/PD 2026 Conference in Copenhagen, Denmark.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.